Timberland Bancorp Inc (TSBK) investors sentiment is 2 in Q4 2017. It’s the same as in 2017Q3. The ratio is neither negative nor positive, as only 36 hedge funds opened new and increased stock positions, while 18 reduced and sold positions in Timberland Bancorp Inc. The hedge funds in our database now possess: 3.61 million shares, up from 3.54 million shares in 2017Q3. Also, the number of hedge funds holding Timberland Bancorp Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 11 Increased: 26 New Position: 10.
The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is a huge mover today! The stock decreased 5.70% or $0.18 during the last trading session, reaching $2.98. About 118,164 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 23, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.The move comes after 7 months negative chart setup for the $114.01 million company. It was reported on Apr, 23 by Barchart.com. We have $2.77 PT which if reached, will make NASDAQ:OMED worth $7.98 million less.
OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $114.01 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.
Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals has $40 highest and $3.0 lowest target. $7.63’s average target is 156.04% above currents $2.98 stock price. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. As per Tuesday, December 20, the company rating was initiated by SunTrust. BMO Capital Markets downgraded OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, April 11 to “Market Perform” rating. The firm earned “Buy” rating on Wednesday, September 9 by Jefferies. The firm has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The firm has “Mkt Perform” rating given on Monday, January 25 by Leerink Swann. JMP Securities maintained the shares of OMED in report on Wednesday, March 9 with “Market Outperform” rating. The company was maintained on Wednesday, August 10 by Jefferies. The stock has “Buy” rating by Cantor Fitzgerald on Monday, April 18. The firm has “Buy” rating by Jefferies given on Tuesday, September 26. H.C. Wainwright maintained the shares of OMED in report on Tuesday, March 20 with “Hold” rating.
Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on May, 14. They expect $-0.24 earnings per share, up 60.66% or $0.37 from last year’s $-0.61 per share. After $0.25 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -196.00% negative EPS growth.
Investors sentiment increased to 1.62 in Q4 2017. Its up 0.91, from 0.71 in 2017Q3. It is positive, as 3 investors sold OncoMed Pharmaceuticals, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Citigroup Inc invested in 100 shares or 0% of the stock. Morgan Stanley has 6,117 shares for 0% of their portfolio. 13,740 were accumulated by Drw Securities. Pdt Prns Ltd Liability owns 59,100 shares or 0.01% of their US portfolio. Tudor Invest Et Al has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Geode Management Ltd Llc accumulated 117,330 shares. State Street invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Disciplined Growth Invsts Mn has 0.03% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Burt Wealth Advsr owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 2,019 shares. Blackrock holds 224,157 shares or 0% of its portfolio. Vanguard Gru has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Endurant Capital L P owns 139,100 shares. Barclays Public Limited Co reported 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Manufacturers Life Insurance The invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Iguana Limited Company has 150,000 shares for 0.4% of their portfolio.
The stock increased 0.58% or $0.19 during the last trading session, reaching $32.76. About 29,786 shares traded or 27.42% up from the average. Timberland Bancorp, Inc. (TSBK) has risen 43.25% since April 23, 2017 and is uptrending. It has outperformed by 31.70% the S&P500.
Since January 1, 0001, it had 0 insider purchases, and 3 sales for $463,292 activity.